newsfilter
← Latest News
GlobeNewswire·

KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

Cardiovascular safety is a key component of the KP1077 product profile; Topline data comparing SDX to other stimulant treatments expected in Q3 2022 CELEBRATION, Fla., April 19, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, o